Arcadia Consumer Healthcare’s Acquisition Of The U.S. Rights To Sanofi’s Kaopectate®

Ropes & Gray counseled Arcadia Consumer Healthcare on the deal.

Arcadia Consumer Healthcare, a portfolio company of Avista Capital Partners, executed the acquisition of the U.S. rights to the Kaopectate® brand from Sanofi.

Kaopectate® has been a leader in the treatment of diarrhea and upset stomach for more than 75 years and has been trusted by millions of Americans during that time. Available in both liquid and caplets, Kaopecate® provides safe and effective relief and is available at all major retailers throughout the US.

Arcadia Consumer Healthcare, Inc., formerly Kramer Laboratories, Inc., is a recognized leader in the consumer healthcare market for over-the-counter medicines. For over 35 years, the company has delivered innovative healthcare products to help consumers self-treat their everyday problems. Avista Capital Partners is a leading middle-market healthcare-focused private equity firm.

The Ropes & Gray team advising Arcadia Consumer Healthcare was led by private equity partners David Blittner (Picture) and Bob Rivollier, and included Arkadiusz Maczka (all of New York).

Involved fees earner: David Blittner – Ropes & Gray; Arek Maczka – Ropes & Gray; Bob Rivollier – Ropes & Gray;

Law Firms: Ropes & Gray;

Clients: Arcadia Consumer Healthcare;

Author: Ambrogio Visconti